advances in lr-mds and hr-mds in 2023 and beyond
Published 9 months ago • 404 plays • Length 1:52Download video MP4
Download video MP3
Similar videos
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
1:13
challenges in risk stratifying lr-mds: insights into genetic upstaging and early transplant
-
1:13
the main treatment goals in lr-mds and how these differ from hr-mds
-
1:22
key advances in mds management
-
1:23
the current landscape of treatment for hr-mds: an update from ash 2023
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
3:08
welcome to the video journal of hematology & hematological oncology 🎥🩸
-
9:25
mgus diagnosis: a step-by-step approach
-
13:39
key highlights in mds: treating lower-risk & higher-risk disease, trial updates, and more
-
1:36
the use of outpatient cilta-cel in the treatment of multiple myeloma
-
3:37
progress in the categorization and treatment of lr-mds
-
0:55
the role of rna modifications in mds and aml
-
1:34
sequencing of agents in lr-mds
-
2:41
an overview of the latest advances in hematology
-
3:41
treatment of anemia in lr-mds: luspatercept and imetelstat
-
1:38
novel treatment options for lr-mds and the importance of clinical trials in this space
-
2:44
latest updates in the treatment of lr-mds: commands and imerge trials
-
2:08
hematological response to frontline treatment in lr-mds is associated with better os
-
2:16
current and future treatment approaches for hr-mds
-
0:58
risk stratification in mds
-
1:09
dec-c plus venetoclax in hr-mds and cmml: an analysis using different response criteria